Porton Biologics establishes CGT CDMO services with $61.4M in financing

By The Science Advisory Board staff writers

April 19, 2021 -- Porton Biologics, a subsidiary of cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) Porton Pharma Solutions, has closed 400 million RMB ($61.4 U.S.) in financing. The funds will be used for the construction and operation of the company's commercial production facility.

The financing will help establish Porton Biologics' adeno-associated virus (AAV) process development and good manufacturing practice (GMP) production capabilities to increase its production capacity for GMP-grade plasmids, viral vectors, cell therapy, and other products supporting gene and cell therapy products.

In November 2020, the company opened its GMP suites for process development and clinical production of plasmids in a phase I project. Now, the series A financing will help the company start up commercial production in the next phase of its project.

Fujifilm picks Holly Springs for new facility
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, announced...
Sorrento advances anti-COVID-19 antibody combo from Mount Sinai
Sorrento Therapeutics and the Icahn School of Medicine at Mount Sinai have entered into an exclusive license agreement for a collection of antibodies...
Arranta Bio adds new manufacturing facility
Arranta Bio is adding a 130,000-sq-ft facility in Boxborough, MA, to complement its facilities in Watertown, MA, and Gainesville, FL, bringing its total...
Fujifilm Diosynth celebrates expansion in Denmark
Contract development and manufacturing organization Fujifilm Diosynth Biotechnologies held a ceremony on March 3 to celebrate the large-scale expansion...

Copyright © 2021 scienceboard.net


Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter